Literature DB >> 32042080

Biomarkers for RBM39 degradation in acute myeloid leukemia.

David Hsiehchen1, Maria Goralski1, Jiwoong Kim2, Yang Xie2,3, Deepak Nijhawan4,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32042080     DOI： 10.1038/s41375-020-0729-9

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Aryl Sulfonamides Induce Degradation of Aryl Hydrocarbon Receptor Nuclear Translocator through CRL4DCAF15 E3 Ligase.

Authors:  Sung Ah Kim; Seung-Hyun Jo; Jin Hwa Cho; Min Yeong Yu; Ho-Chul Shin; Jung-Ae Kim; Sung Goo Park; Byoung Chul Park; Sunhong Kim; Jeong-Hoon Kim
Journal:  Mol Cells       Date:  2020-11-30       Impact factor: 5.034

2.  Genetic and compound screens uncover factors modulating cancer cell response to indisulam.

Authors:  Ziva Pogacar; Kelvin Groot; Fleur Jochems; Matheus Dos Santos Dias; Antonio Mulero-Sánchez; Ben Morris; Mieke Roosen; Leyma Wardak; Giulia De Conti; Arno Velds; Cor Lieftink; Bram Thijssen; Roderick L Beijersbergen; René Bernards; Rodrigo Leite de Oliveira
Journal:  Life Sci Alliance       Date:  2022-05-09

3.  Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker.

Authors:  Rui Zhang; Wei Wang; Nie Zhang; Xueting Chen; Wanming Liu; Longzhen Zhang; Nianli Liu
Journal:  J Cell Mol Med       Date:  2022-08-21       Impact factor: 5.295

Review 4.  Alternative Splicing in Myeloid Malignancies.

Authors:  Carmelo Gurnari; Simona Pagliuca; Valeria Visconte
Journal:  Biomedicines       Date:  2021-12-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.